EXHIBIT 10.43

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

 

AMENDMENT TO 7.0% (SUBJECT TO ADJUSTMENT) CONVERTIBLE
PROMISSORY NOTES DUE OCTOBER 26, 2007

This Amendment to 7.0% (Subject to Adjustment) Convertible Promissory Notes
previously Due September 13, 2005, dated as of October 26, 2007 and currently
due October 26, 2007 (the "Amendment"), is by and among Access Pharmaceuticals,
Inc., a Delaware corporation (the "Company"), and each of Oracle Partners LP,
Oracle Institutional Partners LP, SAM Oracle Investments Inc. and Oracle
Offshore Ltd. (each, a "Holder"), amending certain provisions of those certain
7.0% (Subject to Adjustment) Convertible Promissory Notes Due October 26, 2007
(each as amended and in effect from time to time, a "Note") from the Company to
each Holder in the original principal amount of $2,524,500, $698,500, $660,000
and $132,000, respectively. Terms not otherwise defined herein which are defined
in any Note shall have the same respective meanings herein as therein.

WHEREAS, the Company and each Holder have agreed to modify certain terms and
conditions of each Note as specifically set forth in this Amendment.

NOW, THEREFORE, in consideration of the mutual agreements contained herein and
for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

1. Amendment to Each Note. Each Note is hereby amended as follows:

(a)  The title of each Note is hereby deleted in its entirety and replaced with
the following:

"7.0% (Subject to Adjustment) Convertible Promissory Note Due October 26, 2007."

(b)  All references to "October 26, 2007" in each Note are hereby deleted and
replaced with "November 16, 2007."

2. Condition to Effectiveness. This Amendment shall not become effective until
each Holder receives a counterpart of this Amendment executed by the Company.

3. Ratification, Etc. Except as expressly amended hereby, all terms and
conditions of each Note, as amended, are hereby ratified and confirmed in all
respects and shall continue in full force and effect. Each Note and this
Amendment shall be read and construed as a single agreement. All references to
any Note shall hereafter refer to such Note, as amended hereby.

--------------------------------------------------------------------------------

 
4. No Waiver. Nothing contained herein shall constitute a waiver of, impair or
otherwise affect, any obligation of the Company under any Note or any rights of
any Holder consequent thereon.

5. Counterparts. This Amendment may be executed in one or more counterparts,
each of which shall be deemed an original but which together shall constitute
one and the same instrument.

6. Governing Law. This amendment shall be governed by, and construed in
accordance with, the laws of the State of Texas (without reference to conflict
of laws).

[the remainder of this page is left blank intentionally]
 
 
 
 
 
 
 
 

--------------------------------------------------------------------------------

 
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as a
document under seal as of the date first above written.
 

 Company:          ACCESS PHARMACEUTICALS, INC.        By:  /s/ Stephen B.
Thompson    Name: Stephen B. Thompson    Title: Vice President, Chief Financial
Officer        Holders:          ORACLE PARTNERS LP        By:  /s/ Joel
Liffmann    Name: Joel Liffmann    Title: Authorized Agent       ORACLE
INSTITUTIONAL PARTNERS LP        By:  /s/ Joel Liffmann    Name: Joel Liffmann  
 Title: Authorized Agent        SAM ORACLE INVESTMENTS INC.        By:  /s/ Joel
Liffmann    Name: Joel Liffmann    Title: Authorized Agent        ORACLE
OFFSHORE LTD.        By:  /s/ Joel Liffmann    Name: Joel Liffmann    Title:
Authorized Agent